SCHEMBL2676648

SCHEMBL2676648

CCn1cc(-c2cc(Oc3ccc4nc(NC(C)C5CCCCC5)sc4c3)ccn2)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 13/20 0.44
▸ USP30 Q70CQ3 2/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ PDGFRB P09619 3/20 0.40
▸ PDGFRA P16234 3/20 0.40
▸ FLT3 P36888 3/20 0.40
▸ KIT P10721 2/20 0.40
▸ MET P08581 1/20 0.38
▸ KDR P35968 1/20 0.38
▸ PI4KA P42356 3/20 0.38
▸ PI4KB Q9UBF8 3/20 0.38
▸ PIK3CG P48736 2/20 0.38
▸ PIP5K1C O60331 1/20 0.38
▸ PIK3CD O00329 1/20 0.38
▸ PIK3CA P42336 1/20 0.38
▸ PIK3CB P42338 1/20 0.38
▸ PIM1 P11309 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2676644 1.00 CSF1R (0.44) CSF1RUSP30NPC1MAPTPKM
SCHEMBL2676592 0.94 USP30 (0.40) CSF1RUSP30NPC1MAPTPKM
SCHEMBL2676596 0.94 USP30 (0.40) CSF1RUSP30NPC1MAPTPKM
SCHEMBL14396772 0.92 CSF1R (0.39) CSF1RUSP30NPC1MAPTPKM
SCHEMBL2675982 0.92 CSF1R (0.38) CSF1RUSP30NPC1MAPTPKM
SCHEMBL2675979 0.92 CSF1R (0.38) CSF1RUSP30NPC1MAPTPKM
SCHEMBL4373929 0.92 CSF1R (0.38) CSF1RUSP30NPC1MAPTPKM
SCHEMBL2677406 0.92 CSF1R (0.38) CSF1RUSP30NPC1MAPTPKM
SCHEMBL2675565 0.91 CSF1R (0.39) CSF1RUSP30NPC1MAPTPKM
SCHEMBL2675566 0.91 CSF1R (0.39) CSF1RUSP30NPC1MAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553854-B2 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2009-06-30 — — US claimed
US-8710048-B2 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS AG (CH) 2014-04-29 — — US disclosed
US-20120225861-A1 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2012-09-06 — — US disclosed
US-8173689-B2 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS AG (CH) 2012-05-08 — — US disclosed
US-20100280006-A1 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS AG (CH) 2010-11-04 — — US disclosed
US-7553854-B2 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2009-06-30 — — US disclosed
US-20080045528-A1 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING NOVARTIS AG 2008-02-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225861-A1 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling CSF1R, CSF3R, FLT3 CSF1R 1/4885USP30 3387/4885NPC1 3788/4885
US-20100280006-A1 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling CSF1R, CSF3R, FLT3 CSF1R 1/4885USP30 3387/4885NPC1 3788/4885
US-20080045528-A1 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING CSF1R, CSF3R, FLT3 CSF1R 1/4885USP30 3387/4885NPC1 3788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback